Commons Health Select Committee ‘Brexit – Medicines, medical devices and substances of human origin’ inquiry – second session held

The second oral evidence session of the House of Commons Health Select Committee inquiry on ‘Brexit – Medicines, medical devices and substances of human origin’ was held on Tuesday 12 December 2017. Evidence was heard from the following witnesses:

  • Dr Jayne Spink, Chief Executive, Genetic Alliance UK;
  • Dr Beth Thompson MBE, Head of UK and EU Policy, The Wellcome Trust;
  • Aisling Burnand MBE, Chief Executive, Association of Medical Research Charities;
  • Steve Bates, Chief Executive, BioIndustry Association;
  • Leslie Galloway, Chairman, Ethical Medicines Industry Group;
  • Suzanne Halliday, Head of Medical Devices, British Standards Institution.

The next evidence session will be held on Tuesday 19 December 2017.

Please click here to read the full transcript of the evidence.

Tagged with

Published 13. December 2017 in News UK